Going concern
Filing comparison
InflaRx N.V. disclosed substantial doubt about its ability to continue as a going concern
No going-concern disclosure → Substantial doubt about ability to continue as a going concern
The Company is required to design the clinical trial phase 2b for its izicopan compound, obtain regulatory acceptance and determine the costs for the clinical trial phase 2b in order to seek substantial funding for continuing its operations which raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note B.1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the…
Evidence
- Blank check
- No
- Comparable
- Yes
- Current state
- substantial_doubt
- Current state label
- Substantial doubt about ability to continue as a going concern
- Direction
- escalated
- Located in
- going-concern note
- Prior filed
- 2025-03-20
- Prior form
- 20-F
- Prior state
- none
- Prior state label
- No going-concern disclosure
- Source
- ASC 205-40 going-concern note comparison
- Why
- Disclosure about the company's ability to continue as a going concern changed compared with its previous report.